Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer

Dihge, Looket; Bendahl, Pär‐Ola; Grabau, Dorthe; Isola, Jorma; Lövgren, Kristina; Rydén, Lisa; Fernö, Mårten

doi:10.1007/s10549-007-9645-1

Cited by 57 publications

(55 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, clinical evidence suggested that SRC-3 promoted drug resistance in cancer cells and contributed to poor disease-free survival in patients with breast and lung cancers [3][4][5]. Therefore, a better understanding of how SRC-3 promotes drug resistance and survival in cancer cells is imperative for improving treatment outcomes.…”

Section: Discussionmentioning

confidence: 99%

“…Recent reports indicate that overexpression of oncogene SRC-3 was associated with development of drug resistance and poor disease-free survival in patients with breast cancer [4,5]. To better understand the mechanism by which SRC-3 promotes drug resistance and cell survival, we devised an assay to identify genes that can promote cell proliferation and cell survival when expression of SRC-3 was suppressed in breast cancer cells.…”

Section: Src-3 Regulates Mif Expressionmentioning

confidence: 99%

“…SRC-3 (also known as AIB1 for amplified in breast cancer 1) was initially identified as a gene amplified and overexpressed in 5%-10% of ovarian cancers and 30%-60% of breast cancers [2]. Recent clinical evidence showed that high levels of SRC-3 expression were associated with high levels of HER2/neu, EGFR, development of drug resistance and poor disease-free survival in patients with breast and lung cancers [3][4][5]. These results suggest that crosstalk between signaling pathways regulate SRC-3 activity through protein post-translational modifications (PTMs) [6][7][8].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor

et al. 2012

Cell Res

View full text Add to dashboard Cite

SRC-3/AIB1 (steroid receptor coactivator 3/amplified in breast cancer 1) is an authentic oncogene that contributes to the development of drug resistance and poor disease-free survival in cancer patients. Autophagy is also an important cell death mechanism that has tumor suppressor function. In this study, we identified macrophage migration inhibitory factor (MIF) as a novel target gene of SRC-3 and demonstrated its importance in cell survival. Specifically, we showed that MIF is a strong suppressor of autophagic cell death. We further showed that suppression of MIF, in turn, induced autophagic cell death, enhanced chemosensitivity and inhibited tumorigenesis in a xenograft mouse tumorigenesis model. Our study demonstrated that regulation of MIF expression and suppression of autophagic cell death is a potent mechanism by which SRC-3 contributes to increased chemoresistance and tumorigenicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Src-3 Regulates Mif Expressionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor

et al. 2012

Cell Res

View full text Add to dashboard Cite

show abstract

“…CYP2C9-derived EETs do so by a mechanism involving activation of the EGFR (Michaelis et al, 2003). One study reported high expression of EGFR to be inversely correlated with nodal metastases and shorter, distant disease-free survival in a group of breast cancer patients who had received 2 years of adjuvant tamoxifen treatment (Dihge et al, 2008). This is not fully compatible with our finding, as we found both a higher frequency of nodal involvement with the CYP2C8/9 *3/*1/*2/*1 genotype (in tumours larger than 20 mm) and a higher risk of any type of breast cancer recurrence, especially in women treated with tamoxifen.…”

Section: Discussionmentioning

confidence: 99%

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

et al. 2009

View full text Add to dashboard Cite

BACKGROUND: CYP2C8/9 polymorphisms may influence breast cancer-free survival after diagnosis due to their role in the metabolism of tamoxifen, paclitaxel, and other chemotherapy. cytochrome P450 (CYP)2C8/9 metabolise arachidonic acid to epoxyeicosatrienoic acids, which enhance migration and invasion in vitro and promote angiogenesis in vivo. We aimed to investigate the frequency of CYP2C8/9 polymorphisms in relation to breast tumour characteristics and disease-free survival. METHODS: A prospective series of 652 breast cancer patients from southern Sweden was genotyped for CYP2C8*3, CYP2C8*4, CYP2C9*2, and CYP2C9*3. Blood samples and questionnaires were obtained pre-and postoperatively. Clinical information and tumour characteristics were obtained from patients' charts and pathology reports. RESULTS: Frequencies of CYP2C8/9 polymorphisms were similar to healthy European populations. Significantly less node involvement (P ¼ 0.002) and fewer PR þ tumours (P ¼ 0.012) were associated with CYP2C8*4. Median follow-up was 25 months and 52 breast cancer-related events were reported. In a multivariate model, CYP2C8/9*3/*1*/*2/*1 was the only factor associated with increased risk for early events in 297 tamoxifen-treated, ER-positive patients, adjusted HR 2.54 (95%CI 1.11 -5.79). The effect appeared to be driven by CYP2C8*3, adjusted HR 8.56 (95%CI 1.53 -51.1). CONCLUSION: Polymorphic variants of CYP2C8/9 may influence breast tumour characteristics and disease-free survival in tamoxifentreated patients.

show abstract

“…Three cores from each individual tumor were arrayed. These TMAs have been used for immunohistochemical staining of CK5, CK14, EGFR and cytokeratin clone AE1/AE3, as described previously [16][17][18]. The BRCA1 and BRCA2 tumors were similarly arrayed in a separate TMA.…”

Section: Tumor Characteristics and Tissue Microarraysmentioning

confidence: 99%

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer

Rennstam

McMichael

Berglund

et al. 2009

Breast Cancer Res Treat

Self Cite

View full text Add to dashboard Cite

show abstract

Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer

Cited by 57 publications

References 24 publications

Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor

Steroid receptor coactivator 3 regulates autophagy in breast cancer cells through macrophage migration inhibitory factor

CYP2C8 and CYP2C9 polymorphisms in relation to tumour characteristics and early breast cancer related events among 652 breast cancer patients

Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer

Contact Info

Product

Resources

About